160 related articles for article (PubMed ID: 24222652)
1. Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications.
Magagna-Poveda A; Leske H; Schmid C; Bernays R; Rushing EJ
Swiss Med Wkly; 2013; 143():w13895. PubMed ID: 24222652
[TBL] [Abstract][Full Text] [Related]
2. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
Ramírez C; Cheng S; Vargas G; Asa SL; Ezzat S; González B; Cabrera L; Guinto G; Mercado M
J Clin Endocrinol Metab; 2012 May; 97(5):1745-51. PubMed ID: 22419713
[TBL] [Abstract][Full Text] [Related]
3. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
4. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
Niveiro M; Aranda FI; Peiró G; Alenda C; Picó A
Hum Pathol; 2005 Oct; 36(10):1090-5. PubMed ID: 16226108
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
7. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
8. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
9. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
Onofri C; Theodoropoulou M; Losa M; Uhl E; Lange M; Arzt E; Stalla GK; Renner U
J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
[TBL] [Abstract][Full Text] [Related]
10. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
[TBL] [Abstract][Full Text] [Related]
11. PTTG and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Przegl Lek; 2016; 73(2):53-8. PubMed ID: 27197423
[TBL] [Abstract][Full Text] [Related]
12. NRP-1 expression is strongly associated with the progression of pituitary adenomas.
Lee SW; Lee JE; Yoo CY; Ko MS; Park CS; Yang SH
Oncol Rep; 2014 Oct; 32(4):1537-42. PubMed ID: 25109698
[TBL] [Abstract][Full Text] [Related]
13. Prothymosin-alpha and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Postepy Hig Med Dosw (Online); 2016 Nov; 70(0):1117-1123. PubMed ID: 27892895
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and growth fractions of pituitary adenomas.
Yonezawa K; Tamaki N; Kokunai T
Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815
[TBL] [Abstract][Full Text] [Related]
15. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.
Pisarek H; Pawlikowski M; Kunert-Radek J; Radek M
Endokrynol Pol; 2009; 60(4):240-51. PubMed ID: 19753537
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas.
Al-Dissi AN; Haines DM; Singh B; Kidney BA
J Comp Pathol; 2009 Nov; 141(4):229-36. PubMed ID: 19560781
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker.
Pizarro CB; Oliveira MC; Pereira-Lima JF; Leães CG; Kramer CK; Schuch T; Barbosa-Coutinho LM; Ferreira NP
Neuropathology; 2009 Feb; 29(1):40-4. PubMed ID: 18673444
[TBL] [Abstract][Full Text] [Related]
19. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
Onofri C; Losa M; Uhl E; Stalla GK; Renner U
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):152-7. PubMed ID: 18205092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
